In conclusion, GLS1 inhibition and other glutamine metabolism-targeting strategies have presented themselves as promising approaches for cancer treatment, both through direct targeting of glutamine-addicted tumor cells and through enhancement of the anti-tumor immune response. Here, GLS is linked to neoplasm.